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Résumé en
anglais
OBJECTIVE: Evidence-based medicine is a difficult goal to achieve in rare
diseases where randomized controlled trials are lacking. This report provides
guidelines that capitalize on both the literature and expertise of the French
National Huntington Disease Reference Centre to optimalize pharmacological
therapeutic interventions for Huntington's disease (HD).
MATERIAL AND METHODS: HD experts conducted a systematic analysis of the
literature from 1965 to 2013, using a scoring procedure established by the French
National Authority for Health. These experts offered their views when evidence
was missing to set up provisional guidelines for care in HD. These guidelines were
then scored and amended through two subsequent online questionnaires (using
SurveyMonkey scoring), and one face-to-face meeting with an external
multidisciplinary working group as a step towards validation.
RESULTS: Except for the beneficial effects of tetrabenazine in chorea, none of the
published recommendations were grounded on established scientific evidence.
Second-generation antipsychotics are nevertheless the first choice for patients
with psychiatric manifestations (low level of evidence). All other guidelines are
based on low-level evidence and little professional agreement.
CONCLUSION: Patients' care has greatly improved over the last few years despite
the lack of high-level evidence standards. Guidelines are based on the expertise of
trained specialists from the French National Plan for Rare Diseases. This strategy
should now be extended internationally to promote future studies and to
harmonize worldwide care of HD.
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